Aggressive Prostate Cancer Determined by Diagnostic Tool
|
By LabMedica International staff writers Posted on 15 May 2012 |
|
A nanoparticle test has been developed that distinguishes prostate cancer from normal and benign conditions and has the potential to predict the aggressiveness of prostate cancer quantitatively.
A serum gold particle nanoparticle (AuNP) adsorption assay may answer the biggest challenge for cancer biomarker discovery and early cancer detection when the amount of specific molecules that are released from the tumor to the blood is very small.
Scientists at the University of Central Florida (Orlando, USA) who conducted the assay mixed a serum solution with a citrate-protected AuNP solution and the average particle size of the AuNP solution before and after sample incubation is measured by dynamic light scattering (DLS). The gold nanoparticles detect a specific chemical reaction between a prostate tumor and the human immunoglobulin G (IgG), an abundant protein circulating in the blood.
The IgG likes to stick to the surface of the gold nanoparticles to form a protein corona. This corona can be detected by the DLS technique. The investigators found that when cancer cells are present, they can destroy the IgG in the blood, and this specific interaction is picked up by the gold nanoparticles. This simple test can determine quantitatively how aggressive the prostate tumors are and the likelihood they will metastasize. The team tested out the technique on human tissue samples.
The average diameter of the citrate AuNP is 100 nm and the concentration of the nanoparticle is 10 pM and was obtained from Ted Pella Inc. (Redding, CA, USA). Particle size analysis of the assay solutions was conducted using an automatic DLS instrument, NDS1200, from Nano Discovery Inc. (Orlando, FL, USA). Qun Huo PhD, the lead investigator on the project, said, "Our nanoparticles not only seek out a chemical reaction that is specific to prostate cancer, they can also tell us how aggressive the cancerous cells are likely to be, which can give doctors better information to treat their patients." The study was published on March 9, 2012, in the Journal of Translational Medicine.
Related Links:
University of Central Florida
Ted Pella Inc.
Nano Discovery Inc
A serum gold particle nanoparticle (AuNP) adsorption assay may answer the biggest challenge for cancer biomarker discovery and early cancer detection when the amount of specific molecules that are released from the tumor to the blood is very small.
Scientists at the University of Central Florida (Orlando, USA) who conducted the assay mixed a serum solution with a citrate-protected AuNP solution and the average particle size of the AuNP solution before and after sample incubation is measured by dynamic light scattering (DLS). The gold nanoparticles detect a specific chemical reaction between a prostate tumor and the human immunoglobulin G (IgG), an abundant protein circulating in the blood.
The IgG likes to stick to the surface of the gold nanoparticles to form a protein corona. This corona can be detected by the DLS technique. The investigators found that when cancer cells are present, they can destroy the IgG in the blood, and this specific interaction is picked up by the gold nanoparticles. This simple test can determine quantitatively how aggressive the prostate tumors are and the likelihood they will metastasize. The team tested out the technique on human tissue samples.
The average diameter of the citrate AuNP is 100 nm and the concentration of the nanoparticle is 10 pM and was obtained from Ted Pella Inc. (Redding, CA, USA). Particle size analysis of the assay solutions was conducted using an automatic DLS instrument, NDS1200, from Nano Discovery Inc. (Orlando, FL, USA). Qun Huo PhD, the lead investigator on the project, said, "Our nanoparticles not only seek out a chemical reaction that is specific to prostate cancer, they can also tell us how aggressive the cancerous cells are likely to be, which can give doctors better information to treat their patients." The study was published on March 9, 2012, in the Journal of Translational Medicine.
Related Links:
University of Central Florida
Ted Pella Inc.
Nano Discovery Inc
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Thyroid Test
Anti-Thyroid EIA Test
HPV Molecular Test
BD Onclarity HPV Assay
Latest Clinical Chem. News
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
Channels
Molecular Diagnostics
view channel
Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
Lung cancer care increasingly relies on biomarker-guided patient stratification, but tissue biopsy can be impractical and treatment selection remains difficult for many patients. Blood-based assays that... Read more
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more
